Serina Therapeutics NASDAQ:SER reported insider activity on March 19, 2026, when Chief Scientific Officer Randall Moreadith sold 39,000 shares of common stock at $2.50 per share, yielding proceeds of $97,500. The disposal coincided with a recent period of heightened share-price movement - InvestingPro data shows the stock had rallied roughly 60% over the prior week.
Also on March 19, 2026, Moreadith exercised options to obtain 39,000 shares of Serina Therapeutics common stock at an exercise price of $0.06 per share. The exercise carried a total intrinsic cost of $2,340. Following the option exercise and the concurrent sale of the acquired shares, Moreadith no longer holds any direct common-stock position in Serina Therapeutics.
Market metrics reported alongside the filing indicate Serina's shares currently trade at $2.43, with a market capitalization of $27.18 million. InvestingPro assigns the company a "WEAK" financial health rating and notes there are 13 additional ProTips available for SER investors on that platform.
Corporate developments at Serina remain active on the clinical front. The company has enrolled its first patient in a Phase 1b clinical trial for SER-252, an investigational treatment targeting Parkinson's disease. This trial enrollment follows clearance from the U.S. Food and Drug Administration of Serina's Investigational New Drug application, enabling the company to proceed with the planned clinical study. The Phase 1b study is intended to evaluate the safety and efficacy of SER-252 in patients with advanced Parkinson's disease. Serina is also progressing clinical site activities in Australia as part of its global program.
At the same time, Serina has received a notice from the New York Stock Exchange indicating the company is not meeting certain listing criteria. The notice cites low stockholders' equity and financial losses as the basis for noncompliance. The filing does not detail remedial steps beyond the fact of receipt of the notice.
In a separate market note referenced in the filing, Jefferies highlighted potential benefits to the U.S. energy sector from higher oil prices. The firm pointed to increased domestic energy production and expanded liquefied natural gas exports as possible positive drivers, while also flagging potential regulatory scrutiny on utility rates. Jefferies underscored the role of U.S. energy independence as a supporting factor for power and utilities.
This report presents the transaction filings and associated corporate updates as disclosed. Where information is limited in the filings, the article reflects only the details provided by the company and referenced data sources.